Navigation Links
Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS

BRIDGEWATER, N.J., Dec. 1 /PRNewswire/ -- Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P., announced today that it is launching a new initiative to raise awareness of issues affecting women and people of color living with HIV/AIDS. Through a comprehensive campaign including local educational events, media outreach and a new Web site,, the company is sharing learnings from the GRACE study, the largest clinical trial in North America among women with HIV who had previously taken HIV medications. GRACE, which stands for Gender, Race And Clinical Experience, examined differences in response to an HIV medication in combination with other HIV medications.


The GRACE campaign will include perspectives from study participants, physicians, and advocates. Campaign materials, which will be available in English and Spanish, and supporting activities will address the unique design of the GRACE study and the novel recruitment and retention strategies that were used to encourage women and people of color to enroll and stay in the trial. These novel strategies and the study findings have important implications for the long-term care of women and people of color living with HIV.

"The GRACE study not only provides a new model for HIV research, it also has implications for the care of women and people of color living with HIV," said Dawn Averitt Bridge, Founder and Chair of The Well Project, and a paid consultant on the GRACE study. "GRACE proves that women and people of color can and will participate in clinical trials if they are designed and supported in the right way, and these strategies and support techniques can be applied to the everyday care of people living with HIV."

In the United States, HIV/AIDS is on the rise among women and people of color. Today, women account for more than one-quarter of all new HIV/AIDS diagnoses, and African-American and Latina women represent 79 percent of women living with the disease. Overall, 65 percent of people living with HIV in the United States are people of color. Despite these staggering statistics, women and people of color are under-represented in clinical treatment studies, often due to barriers such as availability of child care, lack of transportation, financial burden, and stigma.

The GRACE study enrolled 67 percent women and 84 percent people of color, despite the fact that these groups are typically less likely to participate in clinical trials. The study was designed in partnership with the HIV community and used unique strategies to encourage women and people of color living with HIV to participate in the trial. For example, GRACE participants could receive support to cover costs associated with study participation, including assistance for travel, childcare and food vouchers, and study sites could access grants for patient support activities such as lunch-and-learn sessions and patient support groups for ongoing education and camaraderie.

"The GRACE trial was made possible through widespread collaboration between Tibotec Therapeutics and the HIV community, providing an example of what needs to be done to truly address disparities in HIV care," said Glenn Mattes, President of Tibotec Therapeutics. "Individuals who participated in GRACE have played a historic role in advancing the understanding of HIV treatment in women and people of color."

GRACE Study Design

GRACE (Gender, Race And Clinical Experience) compared gender differences in the efficacy, safety, and tolerability of PREZISTA (600 mg with 100 mg ritonavir twice daily) in combination with other HIV medications over 48 weeks in HIV-1-infected women and men who have previous treatment experience.

What the HIV Community Can Learn from GRACE

The GRACE study showed that successful management of HIV comes from a combination of support and appropriate treatment. People who are living with HIV can develop a strong network of support by:

-- Identifying friends and family members who will offer encouragement and
-- Drawing on the support of others living with HIV, either on a one-on-
   one basis or by joining a support group for people living with HIV
-- Tapping into local HIV/AIDS service organizations and community groups
   for information and a broad range of assistance and services
-- Partnering with their health care providers to understand their
   treatment options and take an active role in managing their disease

For more information about the GRACE study, local GRACE events, and information for people living with HIV, visit

Selected Important Safety Information

-- PREZISTA does not cure HIV infection or AIDS, and does not prevent
   passing HIV to others
-- PREZISTA, together with Norvir(R), has rarely been observed to cause
   liver problems which may be life-threatening
-- Rarely, PREZISTA has been reported to cause a severe or life-
   threatening rash. Contact your healthcare professional if you develop a

Please see additional Safety Information below


PREZISTA® (darunavir) is a prescription medicine. It is one treatment option in the class of HIV (human immunodeficiency virus) medicines known as protease inhibitors.

PREZISTA is always taken with and at the same time as ritonavir (Norvir®), in combination with other HIV medicines for the treatment of HIV infection in adults. PREZISTA should also be taken with food.

-- The use of other medicines active against HIV in combination with
   PREZISTA/ritonavir (Norvir(R)) may increase the likelihood of your
   overall treatment response. Your healthcare professional will work with
   you to find the right combination of other HIV medicines
-- The long-term effects of PREZISTA therapy are unknown at this time. It
   is important that you remain under the care of your healthcare

PREZISTA does not cure HIV infection or AIDS, and does not prevent passing HIV to others.

Please read Important Safety Information below, and talk to your healthcare professional to learn more about PREZISTA.

Important Safety Information

-- PREZISTA, together with Norvir(R), has rarely been observed to cause
   liver problems which may be life-threatening. It was not always clear
   if PREZISTA caused these liver problems because some patients had other
   illnesses or were taking other medicines. Your healthcare professional
   should do blood tests prior to initiating combination treatment
   including PREZISTA. If you have chronic hepatitis B or C infection,
   your healthcare professional should check your blood tests more often
   because you have an increased chance of developing liver problems

   Talk to your healthcare professional about the signs and symptoms of
   liver problems. These may include yellowing of your skin or whites of
   your eyes, dark (tea-colored) urine, pale-colored stools (bowel
   movements), nausea, vomiting, loss of appetite, or pain, aching or
   sensitivity on your right side below your ribs

-- Skin rashes have been reported in patients taking PREZISTA. Rarely,
   PREZISTA has been reported to cause a severe or life-threatening rash.
   Contact your healthcare professional if you develop a rash
-- Taking PREZISTA with certain medicines could cause serious and/or life-
   threatening side effects or may result in loss of its effectiveness. Do
   not take PREZISTA if you are taking the following medicines:
   dihydroergotamine (D.H.E.45(R), Migranal(R)), ergonovine, ergotamine
   (Cafergot(R), Ergomar(R)), methylergonovine, cisapride (Propulsid(R)),
   pimozide (Orap(R)), oral midazolam, triazolam (Halcion(R)), rifampin
   (Rifadin(R), Rifater(R), Rifamate(R), Rimactane(R)), indinavir
   (Crixivan(R)), lopinavir/ritonavir (Kaletra(R)), saquinavir
   (Invirase(R)), lovastatin (Mevacor(R), Altoprev(R), Advicor(R)),
   pravastatin (Pravachol(R)), simvastatin (Zocor(R), Simcor(R),
   Vytorin(R)), or products containing St. John's wort
-- Before taking PREZISTA, tell your healthcare professional if you are
   taking sildenafil (Viagra(R)), vardenafil (Levitra(R)), tadalafil
   (Cialis(R)), atorvastatin (Lipitor(R)), atorvastatin/amlodipine
   (Caduet(R)), or rosuvastatin (Crestor(R)). This is not a complete list
   of medicines. Be sure to tell your healthcare professional about all
   the medicines you are taking or plan to take, including prescription
   and nonprescription medicines, vitamins, and herbal supplements
-- Tell your healthcare professional if you are taking estrogen-based
   contraceptives (birth control). PREZISTA might reduce the effectiveness
   of estrogen-based contraceptives. You must take additional precautions
   for birth control, such as condoms
-- Before taking PREZISTA, tell your  healthcare professional if you have
   any medical conditions, including allergy to sulfa medicines, diabetes,
   liver problems (including hepatitis B or C), or hemophilia
-- Tell your healthcare professional if you are pregnant or planning to
   become pregnant, or are breastfeeding
   -- The effects of PREZISTA on pregnant women or their unborn babies are
      not known. You and your healthcare professional will need to decide
      if taking PREZISTA is right for you
   -- Do not breastfeed if you are taking PREZISTA. You should not
      breastfeed if you have HIV because of the chance of passing HIV to
      your baby
-- High blood sugar, diabetes or worsening of diabetes, and increased
   bleeding in people with hemophilia have been reported in patients
   taking protease inhibitor medicines, including PREZISTA
-- Changes in body fat have been seen in some patients taking HIV
   medicines, including PREZISTA. The cause and long-term health effects
   of these conditions are not known at this time
-- As with other protease inhibitors, taking PREZISTA may strengthen the
   body's immune response, enabling it to begin to fight infections that
   have been hidden. Patients may experience signs and symptoms of
   inflammation that can include swelling, tenderness, or redness
-- The most common side effects related to taking PREZISTA include
   diarrhea, nausea, headache, and abdominal pain. Uncommon but severe
   side effects such as inflammation of the pancreas and increased blood
   fat levels have also been rarely reported. This is not a complete list
   of all possible side effects. If you experience these or other
   symptoms, talk to your healthcare professional. Do not stop taking
   PREZISTA or any other medicines without first talking to your
   healthcare professional
-- You are encouraged to report negative side effects of prescription
   drugs to the FDA.  Visit, or call 1-800-FDA-1088
-- Please refer to the ritonavir (Norvir(R)) Product Information (PI and
   PPI) for additional information on precautionary measures

This is not a complete list of all adverse drug reactions reported with the use of PREZISTA®. Please see full Prescribing Information for more details. Full prescribing information is also available at

About Tibotec Therapeutics

Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P., headquartered in Bridgewater, N.J., is dedicated to delivering innovative virology therapeutics that help healthcare professionals address serious unmet needs in people living with HIV.

Media Contact:  Pamela Van Houten
Office: 908-541-4137
Mobile: 908-295-7367

SOURCE Tibotec Therapeutics

SOURCE Tibotec Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
2. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
3. Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
4. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
5. Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds
6. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  InCarda Therapeutics, ... development and commercialization of therapies for cardiovascular conditions via ... a subsidiary business in Australia . ... trial in Australia in the ... leading investigators and medical centers in Adelaide ...
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):